Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 January 2021 | Story Igno van Niekerk | Photo Francois van Vuuren (iFlair)
Anton Roodt

 The Afrikaans words, weerlose meganika, can be roughly translated as ‘vulnerable mechanics’. If you do not know the exact meaning of this, rest assured, you are not alone. At least one person does. Anton Roodt of Roodt Architects has been summoning a storm of positive reviews in the literary world with his debut offering, which is neither an environmentally friendly building nor creative historical restoration for which he is renowned, but a book.

Weerlose meganika was written as part of the requirements for Roodt’s fourth MA degree – all obtained at the University of the Free State (UFS), where the Roodts have been part of the UFS family for three generations. Anton’s father was the Head of the department of Architecture, and his son recently completed his studies in the same department. His wife, Zarine, has been involved as lecturer and research fellow in the Department of Communication Science. Roodt’s wide spectrum of interests shows in the variety of his MA degrees (Architecture, Town and Regional Planning, Environmental Management, and now – Creative Writing).

Roodt, renowned for his creativity and innovative manner of working, has barely stepped into the world of literature; yet the book, published by Tafelberg Publishers, is being described in words probably never used by critics: “verrassend vernuwend” (surprisingly refreshing), “baldadig,” (which I can only translate as ‘wildly playful’), and nostalgic science fiction.

In a Zoom conversation, Roodt shared that he wrote mostly in his spare time. Many hours of study in the buzz of architecture classrooms taught him to focus anywhere and anytime. According to Roodt, the chapters that had to be removed in the final edits of Weerlose meganika comprise sufficient material for a second book. 

Anton and his son, Leon-Pierre, both worked on the cover of Weerlose meganika: Anton designed it and Leon-Pierre was responsible for the graphics. Although publishers usually prefer to appoint their own designers, Tafelberg liked and kept the design as presented. This was no surprise, as design is not new to Anton who, as a student, was involved in the design of rag posters. During a particular rag, he realised that the poster design was extremely successful, as about 90% of them were stolen by students from lampposts and other areas. 

Roodt’s recipe for success? He is naturally curious and wants to learn more about many things. This allows him to connect with interesting people such as his fellow students and lecturers (Dr Francois Smith and Prof Henning Pieterse) in the Creative Writing course, where they kept on pushing each other to improve their work. It is clear that Roodt is on a lifelong journey of learning. And, in case you are wondering – yes, he recently started his PhD studies. At the UFS, of course.

When I asked Anton about the strange title, Weerlose meganika, he explained that he has always been fascinated by juxtapositions. He loves bringing seemingly unrelated elements together. 

Looking at the reviews, he has been successful once again. 

*** If you are curious to know more, Weerlose meganika is available at most bookstores, as well as online.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept